Study of Diagnostic Performance of [18F]CTT1057 in BCR
Prostatic Neoplasms · Prostate Cancer · Recurrence
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 190 (final count)
- Started
- Sep 30, 2021
- Main results expected
- Nov 23, 2023
- Fully finished
- Nov 23, 2023
- Results posted
- Mar 12, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Region-level Correct Localization Rate (CLR) of Vidoflufolastat (18F)
Measured over: vidoflufolastat (18F) PET imaging acquired at Day 1 or Day 15 assessed against Composite Truth Standard (CTS) obtained within 8 weeks (before or after) of 18F-CTT PET scan or during follow-up (up to 90 days after radiotherapy for PSA level assessment)
Patient-level Positive Predictive Value (PPV) (With Anatomical Localization) of Vidoflufolastat (18F)
Measured over: vidoflufolastat (18F) PET imaging acquired at Day 1 or Day 15 assessed against Composite Truth Standard (CTS) obtained within 8 weeks (before or after) of 18F-CTT PET scan or during follow-up (up to 90 days after radiotherapy for PSA level assessment)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04838613 · record last updated 2025-10-20 · checked 2026-11-09 15:47 UTC